Please Wait...

Fetuin-A

Biomarker Therapeutic Areas: 
Biomarker Matrices: 

Fetuin A, also known as α-2-HS glycoprotein (AHSG) is a well conserved glycoprotein implicated in the regulation of phosphorus and calcium homeostasis. Fetuin-A has also a role in inflammation and metabolic disease as it binds to minerals, lipids, lectins, proteases and has TGF-β antagonist and insulin receptor antagonist action. Fetuin A is synthetized by the liver and circulates in blood at high concentrations. For example, fetal calf serum contains less albumin than fetuin-A (Jahnen-Dechent et al., 2011). Fetuin-A is also present in calciprotein particles (cytotoxic particles containing inorganic calcium-phosphate crystals and mineral binding proteins) in patient with chronic kidney diseases (Kuro-o, 2013).

Bioclinica Lab employs a manual sandwich immunoassay designed for the measurement of Fetuin A in serum.

Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

With many clinical trials slowed or terminated, investments in new technologies are difficult. Yet, a #CTMS with a… https://t.co/VRIhWWf4tE
Bioclinica (5 days ago)
With Bioclinica #CTMS, sponsors & CROs have access to a full-featured, scalable system - a single, centralized sour… https://t.co/7ACrv8cvuF
Bioclinica (1 week ago)
Now available: a DIY #EDC solution. From study start-up to close-out, Bioclinica EDC Solo is an efficient, cost-eff… https://t.co/vFhC7ITfZV
Bioclinica (2 weeks ago)
Reduce the number of user requirement iterations and UAT findings during the #IRT build process. With the agile app… https://t.co/TJt2sZlrFP
Bioclinica (2 weeks ago)
Don't compromise with manual systems and spreadsheets. As an entry-level system with phased implementation, Bioclin… https://t.co/qIpi1MESXw
Bioclinica (3 weeks ago)
According to our recent poll, 45% of respondents had neither a #CTMS nor an #eTMF system, while only 24% had both.… https://t.co/l4dKC7pBQo
Bioclinica (3 weeks ago)